Vasopressin and Inhaled Prostacyclin in Pediatric Pulmonary Hypertension

To diagnose pulmonary hypertension, children have a cardiac catheterization to check the blood pressure in their lungs. Children with pulmonary hypertension have high blood pressure in their lungs. The right ventricle of the heart has to do more work to pump against this higher pressure. The investigators do not know the best medicine(s) to help children with pulmonary hypertension when their right ventricles fail. The purpose of the study is to look at the effects of two different medicines on the blood pressure in the lungs of a child with pulmonary hypertension. The investigators hope to then be able to choose the best medicine for children with pulmonary hypertension and right ventricular failure.

The first medicine is called vasopressin. It is a hormone that your body makes on its own. The investigators will be giving it through an intravenous infusion. The investigators think that vasopressin works differently in different parts of your body. The investigators are looking to see the different effects that vasopressin has in the lungs compared to the rest of the body.

The second medicine is called prostacyclin and is something that your body also makes by itself. Prostacyclin, given via an intravenous infusion, is a treatment for pulmonary hypertension as it decreases pressure in the blood vessels. In the catheterization laboratory, patients breathe in this medicine to measure specific changes in the blood pressure in their lungs.

Study Overview

• Status: Terminated
• Conditions: Pulmonary Hypertension
• Intervention / Treatment: Drug: Vasopressin infusion; Drug: Vasopressin infusion and epoprostenol inhalation

Detailed Description

Background:

Pulmonary hypertension (PH) is a rare, but devastating disease that affects both adult and pediatric patients. Mortality is high with 84% survival at one year and 50% survival at five years in adult populations despite treatment. The cause of death is typically either from right ventricular failure or sudden cardiac death, likely secondary to a pulmonary hypertensive crisis. The resuscitation of patients with PH after cardiac arrest is extremely difficult. The use of epinephrine, a pulmonary vasoconstrictor, during resuscitation may impair filling of the left ventricle. The ideal resuscitation drug(s) would dilate the pulmonary vascular bed to help fill the left ventricle while constricting the systemic vascular bed to maintain coronary perfusion.

Objectives:

The assessment of pulmonary vascular reactivity is critical to the clinical management of patients with pulmonary hypertension (PH). The goals of this pilot study include determination of the hemodynamic effects of low dose vasopressin infusion and the effects of a combination of low dose vasopressin infusion and inhaled prostacyclin in a population of pediatric patients with PH.

Methods:

The investigators propose a prospective, pilot study to examine the acute hemodynamic effects of low dose vasopressin infusion and the combination of low dose vasopressin infusion and inhaled prostacyclin in pediatric pulmonary hypertension patients. The investigators anticipate recruiting 10 pediatric patients with pulmonary hypertension over the course of one year.

Study Protocol:

The study will be performed in the cardiac catheterization laboratory. All subjects will be intubated and mechanically ventilated for the study as per laboratory protocol. Sedation and anesthesia will be performed at the discretion of the pediatric anesthesiologist to provide a consistent anesthetic during the period of hemodynamic study. Arterial and venous access will be obtained via the femoral approach by standard techniques. Right and left catheterization will be performed to record hemodynamic measurements at baseline and after pulmonary vasoreactivity testing with oxygen and nitric oxide as per usual. Catheterization data to be collected includes right atrial pressure, systolic, diastolic and mean pulmonary artery pressure, pulmonary capillary wedge pressure, systemic arterial pressure, cardiac index, pulmonary vascular resistance (PVR) index, systemic vascular resistance (SVR) index and PVR/SVR ratio. After a period of time to allow for nitric oxide washout, acute vasoreactivity testing to assess the hemodynamic response to low dose vasopressin infusion followed by the combination of low dose vasopressin infusion and inhaled PGI2 will be performed.

• Study Type: Interventional
• Enrollment (Actual): 3
• Phase: Phase 2

Contacts and Locations

Study Locations

• Canada
  • Alberta
    • Edmonton, Alberta, Canada, T6G 2B7
      • Stollery Children's Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: No older than 14 years (Child, Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

All pediatric patients with pulmonary hypertension defined as a mean pulmonary artery pressure ≥ 25mmHg undergoing diagnostic cardiac catheterization for clinical purposes are potential subjects. Subjects must have preserved left ventricular function (ejection fraction ≥ 40 %). Subjects must have parental consent for enrollment.

Exclusion Criteria:

1. Any patient with left ventricular dysfunction (EF < 40%).
2. Any patient with known pulmonary veno-occlusive disease

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
PVR/SVR indexed ratio	Cardiac cath data	Within 15 minutes of intervention

Collaborators and Investigators

• Sponsor: University of Alberta

Study record dates

Study Major Dates

• Study Start: February 1, 2012
• Primary Completion (Actual): September 1, 2016
• Study Completion (Actual): September 1, 2016

Study Registration Dates

• First Submitted: June 8, 2011
• First Submitted That Met QC Criteria: June 8, 2011
• First Posted (Estimate): June 9, 2011

Study Record Updates

• Last Update Posted (Actual): December 19, 2018
• Last Update Submitted That Met QC Criteria: December 14, 2018
• Last Verified: December 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Respiratory Tract Diseases; Lung Diseases; Hypertension; Hypertension, Pulmonary; Physiological Effects of Drugs; Antihypertensive Agents; Vasodilator Agents; Platelet Aggregation Inhibitors; Natriuretic Agents; Hemostatics; Coagulants; Vasoconstrictor Agents; Antidiuretic Agents; Epoprostenol; Vasopressins; Arginine Vasopressin; Tezosentan
• Other Study ID Numbers: 2011-LR-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No